Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 2, 2008, Pages 141-145

  Kokowski, Konrad ^a   Harnack, Ulf ^a   Dorn, David C ^a,b   Pecher, Gabriele ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; IFN assay; Mucin; T cells; Tetramer

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MUCIN; MUCIN 1; TETRAMER; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CD8+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED;

EID: 42349085597     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0011-8     Document Type: Article

References (24)

1. Ada G. (1999): The coming age of tumour immunotherapy. Immunol. Cell Biol., 77, 180-185.
2. Alpan R. S., Zhang M. and Pardee A. B. (1996): Cell cycle - dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res., 56, 4358-4361.
3. Brossart P., Heinrich K. S., Stuhler G., Behnke L., Reichardt V. L., Stevanovic S., Muhm A., Rammensee H. G., Kanz L. and Brugger W. (1999): Identification of HLA-A2-restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood, 93, 4309-4317.
4. Burchell J. M., Mungul A. and Taylor-Papadimitriou J. (2001): O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia, 6, 355-3564.
5. Choi C., Witzens M., Bucur M., Feuerer M., Sommerfeldt N., Trojan A., Ho A., Schirrmacher V., Goldschmidt H. and Beckhove P. (2005): Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood, 105, 2132-2134.
6. Correa I., Plunkett T., Coleman J., Galani E., Windmill E., Burchell J. M. and Taylor-Papadimitriou J. (2005): Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int. J. Cancer, 115, 760-768.
7. Croce M. V., Isla-Larrain M. T., Demichelis S. O., Gori J. R., Price M. R. and Eiras-Segal A. (2003): Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res. Treat., 81, 195-207.
8. Disis M. L., Knutson K. L., Schiffman K., Rinn K. AND McNeel D. G. (2000): Preexistent immunity to the HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat., 62, 245-252.
9. Gendler S. J., Lancaster C. A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J. M., Pemberton L., Lalani E. L. AND Wilson D. (1990): Molecular cloning and expression of human tumour-associated epithelial mucin. J. Biol. Chem., 265, 15286-15293.
10. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., Taylor-Papadimitriou J. (1989): A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer, 43, 1072-1076.
11. Gûckel B., Rentzsch C., Nastke M. D., Marmé A., Gruber I., Stefanoviæ S., Kayser S. and Wallwiener D. (2006): Pre-existing T cell immunity against mucin-1 in breast cancer patients and healthy volunteers. J. Cancer Res. Clin. Oncol., 132, 265-274.
12. Kaklamanis L., Leek R., Koukourakis M., Gatter K. C. and Harris A. L. (1995): Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res., 55, 5191-5194.
13. Kan-Mitchell J., Bisikirska B., Wong-Staal F., Schaubert K. L., Bajcz M., Bereta M. (2004): The HIV-1 HLA-A2-SLYNTVATL is a help independent CTL epitope. J. Immunol., 172, 5249-5261.
14. Karanikas V., Colau D., Baurain J. F., Chiari R., Thonnard J., Gutierrez-Roelens I., Goffinet C., Van Schaftingen E. V., Weynants P., Boon T. and Coulie P. G. (2001): High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res., 61, 3718-3724.
15. McDermott R. S., Beuvon F., Pauly M., Pallud C., Vincent-Salomon A., Mosseri V., Pouillart P. and Scholl S. M. (2002): Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology, 70, 324-332.
16. Musselli C., Ragupathi G., Gilewski T., Panageas K. S., Spinat Y. and Livingston P. O. (2002): Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer, 97, 660-667.
17. Nagorsen D., Scheibenbogen C., Schaller G., Leigh B., Schmittel A., Letsch A., Thiel E. and Keilholz U. (2003): Differences in T cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int. J. Cancer, 105, 221-225.
18. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H. and Ohtani H. (1998): CD8+ T cells infiltrated within cancer cells nests as a prognostic factor in human colorectal cancer. Cancer Res., 58, 3491-3494.
19. Plunkett T. A., Correa I., Miles D. W. and Taylor-Papadimitriou J. (2001): Breast cancer and the immune system: opportunities and pitfalls. J. Mammary Gland Biol. Neoplasia, 6, 467-475.
20. Rentzsch C., Kayser S., Stumm S., Watermann I., Walter S., Stefanovic S., Wallwiener D. and Guckel B. (2003): Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin. Cancer Res., 9, 4376-4386.
21. Rosenberg S. A. (2001): Progress in human tumour immunology and immunotherapy. Nature, 411, 380-384.
22. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J. and Schreiber R. D. (2001): IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
23. Schumacher K., Haensch W., Roefzaad C. and Schlag P. M. (2001): Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res., 61, 3932-3936.
24. Whiteside T. L. (2004): Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol. Immunother., 53, 865-878.